Your browser doesn't support javascript.
loading
[Multidrug resistance in chronic lymphocytic leukemia]. / Multidrogrezisztencia-vizsgálatok krónikus lymphoid leukaemiában.
Szendrei, Tamás; Magyarlaki, Tamás; Kovács, Gábor; Nagy, Agnes; Szomor, Arpád; Molnár, Lenke; Dávid, Mariann; Tokés-Füzesi, Margit; Rideg, Orsolya; Pótó, László; Pajor, László; Kajtár, Béla; Losonczy, Hajna.
Afiliación
  • Szendrei T; Pécsi Tudományegyetem, Orvostudományi és Egészségtudományi Centrum I Belgyógyászati Klinika, Hematológiai Osztály, Pécs, Hungary. tomasso81@freemail.hu
Orv Hetil ; 149(4): 161-7, 2008 Jan 27.
Article en Hu | MEDLINE | ID: mdl-18201958
ABSTRACT

INTRODUCTION:

New prognostic factors discovered in chronic lymphocytic leukemia have recently got into the center of clinical interest. While the predictive value of cytogenetical abnormalities, immunoglobulin heavy chain gene mutation status, CD38 and ZAP70 expression is already well known, the significance of multi-drug resistance in chronic lymphocytic leukemia is not well characterized.

AIMS:

The goal of this study was to characterize the multidrug resistance features in 82 patients with chronic lymphocytic leukemia at the genetical, expression- and functional level and to compare it with the patient's clinical behavior (survival and response to therapy).

METHODS:

Light Cycler Real Time PCR based "Single Nucleotide Polymorphism" analysis of the MDR1 gene, as a biological predictor of the expression level of P-glycoprotein was tested in 66 patients with chronic lymphocytic leukemia. P-glycoprotein expression and MDR-function was detected in 82 cases by flow cytometry (by use of anti-P-glycoprotein monoclonal antibody and calcein-verapamil functional test). Response to therapy was analyzed by statistical Fisher-test in the treated 35 patients. The survival analysis (Log-rank test) was performed on the whole population ( n = 82).

RESULTS:

No significant correlation was found between the three levels of multidrug resistance (genetics, phenotype, function) in our patients with chronic lymphocytic leukemia. P-glycoprotein positive cases (n = 9) were predominantly non-responders (8/9, 89%). There must be, however, other mechanisms causing non-response (total non-responders 13/35 treated cases). Most of P-glycoprotein negative CLL patients (n = 26) responded well (21/26, 80%) to chemotherapy (responders 22/35 treated CLL) (p < 0,001). The tendency was the same in the average expected survival rate between P-glycoprotein positive and negative patients (84 vs 203 months) but the difference was not significant (p = 0,106).

CONCLUSIONS:

This study proved the clinical prognostic significance of P-glycoprotein expression of leukaemic cells predicting the chemotherapy response and partially estimating the general survival of patients suffering from chronic lymphocytic leukemia.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Biomarcadores de Tumor / Miembro 1 de la Subfamilia B de Casetes de Unión a ATP / Resistencia a Múltiples Medicamentos / Resistencia a Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: Hu Revista: Orv Hetil Año: 2008 Tipo del documento: Article País de afiliación: Hungria

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Biomarcadores de Tumor / Miembro 1 de la Subfamilia B de Casetes de Unión a ATP / Resistencia a Múltiples Medicamentos / Resistencia a Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: Hu Revista: Orv Hetil Año: 2008 Tipo del documento: Article País de afiliación: Hungria